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REPORT
Pathogenic Variants in GPC4 Cause
Keipert Syndrome
David J. Amor,1,2 Sarah E.M. Stephenson,1,2 Mirna Mustapha,3 Martin A. Mensah,4
Charlotte W. Ockeloen,5 Wei Shern Lee,1,2 Rick M. Tankard,6,7 Dean G. Phelan,1,2 Marwan Shinawi,8
Arjan P.M. de Brouwer,9 Rolph Pfundt,5 Cari Dowling,10 Tomi L. Toler,8 V. Reid Sutton,11,12
Emanuele Agolini,13 Martina Rinelli,13 Rossella Capolino,14 Diego Martinelli,15 Giuseppe Zampino,16
Miroslav Dumic,17 William Reardon,18 Charles Shaw-Smith,19 Richard J. Leventer,1,2,20
Martin B. Delatycki,1,2 Tjitske Kleefstra,9 Stefan Mundlos,4 Geert Mortier,21 Melanie Bahlo,6,7
Nicola J. Allen,10 and Paul J. Lockhart1,2,*
Glypicans are a family of cell-surface heparan sulfate proteoglycans that regulate growth-factor signaling during development and are
thought to play a role in the regulation of morphogenesis. Whole-exome sequencing of the Australian family that defined Keipert syn-
drome (nasodigitoacoustic syndrome) identified a hemizygous truncating variant in the gene encoding glypican 4 (GPC4). This variant,
located in the final exon of GPC4, results in premature termination of the protein 51 amino acid residues prior to the stop codon, and in
concomitant loss of functionally important N-linked glycosylation (Asn514) and glycosylphosphatidylinositol (GPI) anchor (Ser529)
sites. We subsequently identified seven affected males from five additional kindreds with novel and predicted pathogenic variants in
GPC4. Segregation analysis and X-inactivation studies in carrier females provided supportive evidence that the GPC4 variants caused
the condition. Furthermore, functional studies of recombinant protein suggested that the truncated proteins p.Gln506* and p.Glu496*
were less stable than the wild type. Clinical features of Keipert syndrome included a prominent forehead, a flat midface, hypertelorism,
a broadnose, downturned cornersofmouth, anddigital abnormalities,whereas cognitive impairment anddeafnesswere variable features.
Studies of Gpc4 knockout mice showed evidence of the two primary features of Keipert syndrome: craniofacial abnormalities and digital
abnormalities. Phylogenetic analysis demonstrated that GPC4 is most closely related to GPC6, which is associated with a bone dysplasia
that has a phenotypic overlap with Keipert syndrome. Overall, we have shown that pathogenic variants in GPC4 cause a loss of function
that results in Keipert syndrome, making GPC4 the third human glypican to be linked to a genetic syndrome.
Keipert syndrome, also known as nasodigitoacoustic syn-
drome (MIM: 255980), is a rare, X-linked disorder char-
acterized by craniofacial and digital abnormalities and
variable learning difficulties and sensorineural deafness.1
Keipert et al.2 first described the syndrome in two brothers,
and it has subsequently been reported in one other male
sibling pair,3 five isolated male individuals,4–7 and a girl
and her less severely affected father.8 The facial appearance
is distinctive and comprises a broad forehead, hypertelor-
ism, a prominent nose, a widemouth, and a prominent up-
per lip with a cupid’s bow configuration. Changes of the
digits are also distinctive: there is widening of all distal
phalanges, particularly those of the thumbs and great toes.
Previously, we described the diagnosis of Keipert syn-
drome in thematernal nephew of the brothers originally re-
ported by Keipert et al.2 and mapped Keipert syndrome to
Xq22.2-Xq28 in this family (KS1).1 To identify the under-
lying genetic cause of Keipert syndrome, we performed
whole-exome capture and massively parallel sequencing
of gDNA isolated from the maternal nephew (Figure 1A,
KS1 II:5). Institutional ethics approval was provided by
the Royal Children’s Hospital (Melbourne), and written
informed consent was received from all participants
prior to study. Three variants were identified within the
linkage region after exclusion of synonymous variants
and filtering against population databases (Table S1). The
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nonsynonymous variant in the gene encoding the arginine
vasopressin receptor-2 (AVPR2, c.743G>A [p. Arg248His],
GenBank: NM_000054.5) was excluded because it was clas-
sified as a variant of uncertain significance (VUS) according
to ACMG guidelines, and pathogenic variants in this
gene cause diabetes insipidus (MIM: 300538). A truncating
variant in the gene encoding melanoma-associated antigen
(mutated) 1-like 1 was identified (MUM1L1, c.1404G>A
[p.Trp468*], GenBank: NM_001171020.2). This variant
was classified as a VUS and was not considered to be
a strong candidate for Keipert syndrome. Moreover, anal-
ysis of the Genotype-Tissue Expression (GTEx) database
demonstrated negligible expression of MUM1L1 in all tis-
sues except ovary, and dysregulation is associated with
ovarian cancers.9 Analysis of the gene in gnomAD revealed
moderate evidence of gene intolerance to loss of function10
(pLI ¼ 0.49; observed/expected ¼ 0.2, CI 0.09–0.53). The
third variant, which was identified as most likely to be
Figure 1. Pedigree Structure and Segregation of Pathogenic Variants in GPC4
(A) Pedigrees showing the clinical phenotypes and segregation of the WT (þ) and mutant () GPC4 allele. Affected individuals are
shaded, Y indicates the Y chromosome, and carrier females are indicated by a dot.
(B) Representative images of X-inactivation analysis in one carrier female from families KS1 (I:1), KS2 (I:2), and KS3 (I:1) demonstrate
extreme skewing of X inactivation, as evidenced by the inability of the methylation-sensitive restriction endonuclease HpaII to digest
one alleleof the androgen receptor (gray arrow). The secondallele,withminimalmethylation (blackarrow), is almost fullydigestedbyHpaII.
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disease causing, was a hemizygous C-to-T transition variant
in the ninth and final exon of glypican 4; this variant
resulted in premature protein termination (GPC4,
c.1516C>T [p.Gln506*], GenBank: NM_001448.2). GPC4
is classified as extremely intolerant of loss-of-function vari-
ants (pLI ¼ 0.94; observed/expected ¼ 0.11, CI 0.04–0.36)
and is expressed during development in a variety of tissue
types relevant to Keipert syndrome. Notably, GPC4 is a
member of the glypican protein family, whose members
are cell-surface heparan sulfate proteoglycans that regulate
growth-factor signaling during development.11,12 Sanger
sequencing confirmed the variant and segregation within
the KS1 pedigree (Figure 1A).
Further interrogation of the gnomAD database identified,
from within the 182,000 sequenced alleles, two hemizy-
gous alleles predicted to be loss of functionwith high-confi-
dence (LoF allele frequency ¼ 1.1 3 105; c.283C>T,
[p.Gln95*], and c.1150C>T, [p.Arg384*]), even though the
database is considered to be relatively free of sequences
from individualswithpediatricdisorders.Wedidnot believe
thiswouldexcludeGPC4as thegeneunderlying thedisorder
in family KS1 because the phenotype within the family is
quite variable. For example, KS1 II-5 has subtle phenotypic
features and minimal impairment from his condition; he
has a job and has fathered a child. We consider it likely
that the phenotype of Keipert syndrome in some cases
might escape clinical recognition and therefore be included
in gnomAD. This situation has been observed for other
craniofacial syndromes with phenotypic heterogeneity; for
example, gnomAD contains two individuals who have the
pathogenic p.Pro250Arg FGFR3 variant that causesMuenke
syndrome but presents with variable phenotypes.13
We next searched for additional individuals with patho-
genic variants inGPC4 to provide genetic validation of fam-
ily KS1. Five affected males from three additional kindreds
with novel variants in GPC4 were recruited to this study
throughGeneMatcher (Figure 1A).14 In family KS2, a frame-
shift variant was identified in exon 3 in two brothers and a
male cousin (c.701dup [p.Val235Glyfs*53]). In family KS3,
a truncating variant was identified in exon 9 in one affected
male (c.1486G>T [p.Glu496*]), and in family KS4, a
frameshift variant was identified in exon 2 (c.316delG
[p.Asp106Metfs*15]) in one affected male. Notably, no
potentially pathogenic variants were identified in either
AVPR2 or MUM1L1 in these cases. In addition, two addi-
tional familieswere identifiedduring thecourseof the study.
In family KS5, a frameshift variant (c.1518_1521dupGTGC
[p.Pro508Valfs*6]) was identified in exon 9 in one affected
male, and in family KS6, a frameshift variant (c.742delC
[p.Leu248Cysfs*2]) was identified in exon 4 in one affected
male.Genotype analysis in all available samples fromthe six
families confirmed segregation of the variants with disease
and demonstrated inheritance from a carrier mother
(Figure 1A). In the two multigenerational families (KS1
and KS2), this analysis also confirmed that the variant was
present in a carrier grandmother. Transmission of the
variant was observed through nine segregating meioses in
total, providing additional genetic support for the linkage
and gene-identification findings. Carrier females were clini-
cally unaffected, although the mother of KS4 I:1 was noted
tohavepossible subtle dysmorphic features such ashyperte-
lorism and a flat nasal bridge. To assess the X chromosome
inactivationprofileof carrier females,weperformedmethyl-
ation-specific analysis of the (CAG)n repeat of the androgen
receptor gene, essentially as described previously.15 In this
assay, differential methylation of the X chromosomes is
quantitated by methylation-sensitive digestion of genomic
DNA.Allelic ratios from50%–79%wereconsidered to reflect
a normal X-inactivation pattern, from 80%–90% were
considered to reflect moderate skewing, and >90% were
considered to reflect strong skewing. In total, we analyzed
six individuals from four families (KS1 I:1 and II:2; KS2 I:2
and II:6; KS3 I:1; and KS4 I:1). Although analysis of the
(CAG)n repeat was not informative in family KS4, X-inacti-
vation studies in all the carrier females from KS1, KS2, and
KS3 showed extreme skewing of >90% methylation of
one allele (representative results are shown in Figure 1B).
Collectively, these observations provide significant support
for X linkage in the families and strongly suggest that vari-
ants in GPC4 underlie Keipert syndrome.
Interestingly, with the exception of the first family (KS1)
described with Keipert syndrome, all GPC4 variants were
detected via a ‘‘genotype-first’’ approach, yet these indi-
viduals share very similar phenotypes with the original
kindred (Figures 2A–2O and Table 1). Clinical features pre-
sent in seven or more of the ten affected individuals were
macrocephaly, a prominent forehead, a flatmidface, hyper-
telorism, a broad nose, downturned corners of mouth,
and digital abnormalities. The most prominent peripheral
skeletal features were brachydactyly, clinodactyly and/or
camptodactyly, broad terminal phalanges, and broad
thumbs and great toes. Cognitive impairment was variable;
intellectual ability ranged from average to moderate intel-
lectual disability, and autism or autistic features were
observed in three affected individuals. Identification of
these newly reported cases enabled us to extend and refine
the phenotype of Keipert syndrome. In particular, the spec-
trum of digital abnormalities was broadened: absent toe-
nails were observed in individuals KS2 III:2 and KS3 II:1.
The latter individual also had synostosis between metatar-
sals III and IV in the right foot and a missing metatarsal III
with hypoplastic phalanx in the left foot. Although senso-
rineural deafnesswas described initially as a cardinal feature
of Keipert syndrome,1,2 we did not observe deafness in any
of the other families with confirmed GPC4 pathogenic
variants, suggesting that deafness might be relatively infre-
quent inKeipert syndrome. To further test this,we obtained
genomic DNA from one female and three male individuals
previously described as having a clinical diagnosis of Kei-
pert syndrome5,7,8 Three of the four affected individuals
were reported to have moderate sensorineural hearing
loss. However, GPC4 variants were not detected in any,
suggesting that these individuals have an overlapping but
distinct disorder.
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All identified variants were truncating or resulted in
a frameshift, suggesting loss of function as the likely
disease mechanism. The variants in exon 2 (c.316delG
[p.Asp106Metfs*15]), exon 3 (c.701dup [p.Val235Glyfs*
53]), and exon 4 (c.742delC [p.Leu248Cysfs*2]) result
in loss of >50% of the 556 amino acid protein and
Figure 2. Clinical Presentation of Subjects with Keipert Syndrome and Mutations in GPC4
(A–I) Facial features of individuals, demonstrating hypertelorism, a broad forehead, a broad nose, a flat midface, prominent lips, and
downturned corners of mouth. Illustrated are (A) KS1 II:5 at age 15 months, (B) KS1 II:6 at age 5 years, (C and D) KS2 III:1 at age 12 years
and 19 years, (E, F, and G) KS2 III:2 at ages 7 years and 17 years, (H) KS4 II:1 at age 3 years, and (I) KS5 II:2 at age 2 years.
(J) Right hand of KS2 III:1, showing brachydactyly and broad terminal phalanges.
(K–L) Left hand and right foot of KS5 II:2, showing brachydactyly and a broad great toe.
(M) Right foot of KS2 III:2, showing clinodactyly and broad terminal phalanges.
(N–O) Right foot of KS3 II:1, showing synostosis between metatarsals III and IV.
(P) Schematic representationof the locationofpathogenicvariants identified inGPC4and theexonandproteindomainstructure.The signal
peptide sequence (green), phosphoserine (red), glycosylation (orange), lipidation (dark blue), and cleaved GPI anchor (pink) are indicated.
The gene structure was derived from the UCSC Genome Bioinformatics database, and protein coordinates were obtained from Uniprot.
Informed consent for publication of photos was obtained from all individuals or their parents.
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Table 1. Clinical Features and GPC4 Variants of Affected Individuals
Family KS1 KS1 KS1 KS2 KS2 KS2 KS3 KS4 KS5 KS6 Summary
Pedigree ID II:5 II:6 III:3 III:1 III:2 III:6 II:1 II:1 II:2 II:1
Gene variant c.1516C>T
(p.Gln506*)
c.1516C>T
(p.Gln506*)
c.1516C>T
(p.Gln506*)
c.701dup
(p.Val235Glyfs*53)
c.701dup
(p.Val235Glyfs*53)
c.701dup
(p.Val235Glyfs*53)
c.1486G>T
(p.Glu496*)
c.316delG,
p.(Asp106Metfs*15)
c.1518_
1521dupGTGC
(p.Pro508Valfs*6)
c.742delC
(p.Leu248Cysfs*2)
Age at last
examination
40 years 38 years 7 months 19 years 12 years 6 years 3 years 6 years 2 years 3 years
Gender male male male male male male male male male male
Facial Features
Macrocephaly no yes yes no no yes borderline yes yes yes 7/10
Prominent
forehead
yes yes yes no yes unknown yes yes no yes 7/9
Flat midface yes yes yes yes yes unknown yes yes no no 7/9
Hypertelorism yes yes yes yes yes unknown yes yes yes yes 9/9
Broad nose yes yes yes yes yes unknown yes yes yes yes 9/9
Downturned
corners of
mouth
yes yes yes yes yes unknown yes no yes no 7/9
Prominent lip yes yes yes yes yes unknown yes no no no 6/9
Ears simple or
low set
yes no no yes no unknown no yes yes yes 5/9
Skeletal
Brachydactyly yes yes no yes no unknown yes no yes no 5/9
Clinodactyly yes yes yes no yes unknown yes no no no 5/9
Camptodactyly yes yes yes no no unknown no no no no 3/9
Broad thumb yes yes yes no no unknown no no yes yes 5/9
Broad first toe yes yes yes yes no unknown yes no yes yes 7/9
Broad terminal
phalanges
yes yes yes yes yes yes yes no no no 7/10
Other Features
Sensorineural
hearing loss
moderate
unilateral
severe
bilateral
moderate
bilateral
no no unknown no no no no 3/9
Cognitive
impairment
no mild
intellectual
disability
learning
difficulties
moderate
intellectual
disability (IQ 52)
borderline
intellectual
disability (IQ 76)
no (IQ 92) borderline
intellectual
disability (IQ 70)
intellectual
disability
probable yes 8/10
(Continued on next page)
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were classified as pathogenic. However, the truncating
variants in families KS1, KS3, and KS6 (c.1516C>T
[p.Gln506*], c.1486G>T [p.Glu496*]), and c.1518_
1521dupGTGC [p.Pro508Valfs*6]) are within the last
exon and therefore might not be subject to nonsense-
mediated decay. Although the resultant proteins lack
glycosylation sites and the glycosylphosphatidylinositol
(GPI) anchor (Ser529) that are critical for sorting and
localization of GPC proteins (Figure 2P), it is possible
that the variants do not result in a loss of function. To
further test the pathogenic mechanism underlying
p.Glu496* and p.Gln506*, we analyzed recombinant
N-terminal V5-tagged GPC4 in cultured cells. We have
previously utilized similar methodology to investigate
the function of glypicans in the formation of active syn-
apses.16 Expression constructs encoding V5-tagged wild-
type (WT) or truncated (p.Glu496* and p.Gln506*) re-
combinant human GPC4 were transfected into HEK293
cells, and stably transfected populations were isolated af-
ter 3 weeks of culturing in media supplemented with
400 mg/mL geneticin (G418 sulfate, ThermoFisher Scien-
tific). Qualitative visualization of the cell populations by
immunocytochemical analysis with an antibody directed
against V5 suggested reduced amounts of the mutant
GPC4 proteins compared to WT (data not shown). There-
fore, we performed immunoblot analysis to determine
steady-state amounts of GPC4 under basal conditions
and after inhibition of the ubiquitin proteasome system
(UPS), the major intracellular protein degradation
pathway for short-lived or damaged proteins. Cells
were cultured overnight in basal media or media
supplemented with 10 mM MG-132, which we have pre-
viously shown is sufficient to inhibit the UPS without
causing significant cellular toxicity in HEK293 cells.17
Protein extracts were prepared, and immunoblot anal-
ysis, performed essentially as previously described,18
identified an apparent increase in the steady-state
amounts of mutant but not WT recombinant V5 GPC4
after proteasome inhibition (Figure 3A). Quantitation
and comparison of the recombinant GPC4/b-actin ratio
in the untreated cells suggested the steady-state amount
of p.Gln506* was reduced in comparison to that of the
WT (WT 0.026 5 0.002 vs p.Gln506* 0.014 5 0.002,
mean 5 SEM, p ¼ 0.042), whereas there was no signifi-
cant difference in the amounts of p.Glu496* compared
to WT (WT 0.026 5 0.002 vs p.Glu496* 0.029 5
0.004, mean 5 SEM, p ¼ 0.565). In contrast, after expo-
sure to 10 mM MG-132 for 14 h, both p.Gln506* and
p.Glu496* steady-state amounts were significantly
elevated in comparison to steady-state amounts in the
treated WT cells (WT 0.030 5 0.002 vs p.Gln506*
0.041 5 0.003, mean 5 SEM, p ¼ 0.024; and WT
0.030 5 0.002 vs p.Glu496* 0.199 5 0.009, mean 5
SEM, p ¼ 0.002) (Figure 3B). Therefore, having an active
UPS resulted in a relative decrease in steady-state protein
amounts of 2.5-fold for p.Gln506* and 6-fold for
p.Glu496* compared to those in UPS-inhibited cells.Ta
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Collectively, the reduced stability and removal of critical
protein domains suggest a loss of GPC4 function as the
pathogenic mechanism underlying disease in all six fam-
ilies described in this study.
To date, there has been very limited information about
GPC4-associated phenotypes in humans. A hemizygous
missense variant (c.1235G>A [p.Arg412Lys]) was reported
as likely pathogenic in an individual with a Robinow-syn-
drome-like phenotype that included some findings seen in
Keipert syndrome; such findings included macrocephaly;
hypertelorism; broad thumbs and great toes; and campto-
dactyly. However, this individual had more prominent
skeletal features, including mesomelia and cranial scle-
rosis,19 which were not seen in the Keipert-syndrome-
affected individuals with truncating GPC4 mutations in
our study. Duplication of GPC4 has also been implicated
in one family that is affected by the overgrowth syndrome
Simpson-Golabi-Behmel syndrome (SGBS, MIM: 312870),
an X-linked disorder caused by pathogenic variation in
the gene encoding glypican 3 (GPC3). SGBS is character-
ized by pre- and postnatal overgrowth, skeletal abnor-
malities, variable intellectual disability, and congenital
anomalies such as congenital heart defects and diaphrag-
matic hernia.20–22 This SGBS-affected family, initially re-
ported by Golabi and Rosen,21 was followed up on and
was reported in 2010 as not having a GPC3 mutation but
as having a duplication of exons 1–9 ofGPC4.23 This dupli-
cation segregated with a phenotype that included macro-
somia, coarse facies, a short nose, a broad nasal bridge,
macroglossia, and accessory nipples. The duplication map-
ped close to the 30 end of GPC3, and the authors specu-
lated that the duplication might result in decreased
expression of GPC3, or alternatively that GPC4 might be
a second gene for SGBS.23 However, since that publication,
sequencing and deletion analysis ofGPC4 in other individ-
uals with SGBS and other overgrowth disorders has not de-
tected any pathogenic variants.20,24
There have been two reports of SGBS associated with
deletions that encompass bothGPC3 andGPC4. In a family
that included some members with a clinical diagnosis of
SGBS and that was originally described by Pilia et al.,22 a
deletion that removed the entire GPC4 gene and the last
two exons of GPC3 was detected.25 The SGBS phenotype
in males in this family was noted to include renal-tract
abnormalities and hydrocephalus. The second report was
of a 1 Mb deletion encompassing three genes, GPC4,
GPC3, and CCDC160, in a male fetus that was terminated
at 24weeks; his phenotype comprisedmacrosomia, viscero-
megaly, macroglossia, polyhydramnios, and mild ventricu-
lomegaly.26 In both families, there was insufficient clinical
information provided to allow determination of whether
an overlapping phenotype, comprising features of both
SGBS and Keipert syndrome, might have been present.
Glypicans are a family of cell-surface heparan sulfate
proteoglycans characterized by a GPI anchor that localizes
them to the cell surface, where they regulate growth-factor
signaling during development and disease.27 They are
expressed predominantly during development and are
thought to play a role in the regulation of morphogenesis.
In mammals, there are six glypicans, GPC1 to GPC6. The
genes encoding GPC3 and GPC4 and those encoding
GPC5 and GPC6 are clustered on chromosome Xq26 and
chromosome 13q32, respectively, suggesting that the
glypican family arose as a result of gene duplication. Fil-
mus et al.28 reported evidence of homologs of glypican
throughout Eumetazoa but were unable to identify glypi-
can homologs outside the Metazoa linage. To analyze the
evolution of the glypican family, we used the maximum
likelihood method with Molecular Evolutionary Genetics
Analysis (MEGA) software version 6,29 and in doing this,
Figure 3. Truncated GPC4 Proteins Are
Unstable and Degraded by the UPS
(A)HEK293cells transfectedwith constructs
encodingN-terminally taggedWTand trun-
cated GPC4 were grown in the absence or
presence of 10 mM MG-132 for 14 hours.
Total protein was isolated and analyzed
by SDS-PAGE and immunoblotting with
antibodies directed against V5 (46-0705,
ThermoFisher Scientific, 1:5000) and
b-actin (A5441, Sigma; 1:20,000). A repre-
sentative image is shown, and approximate
sizes in kDa are indicated (MultiMark Stan-
dard, Invitrogen).
(B) Quantification of three independent
experiments performed in triplicate. The
immunoreactive signals were quantified
with a LAS4000 imager. Steady-state pro-
tein amounts are expressed as the ratio of
GPC4/b-actin, which is the loading control
for normalization.
An asterisk denotes p % 0.05; statistical
comparisons were made with a two-tailed
t test; error bars represent mean5 SEM.
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we independently replicated the Eumetazoa result. In
addition, evidence of glypicans was identified in the ge-
nomes of both the Placozoa Trichoplax adhaerens and
the sponge Amphimedon queenslandica. These genomes
represent the basal group of multicellular organisms
(Figure S1). To determine the orthology of the glypican
family, we performed phylogenetic analysis by using
the maximum likelihood method. There are two major
glypican subfamilies, the GPC-I subfamily, which com-
prises GPC1, GPC2, GPC4, and GPC6, and the GPC-II sub-
family, which comprises GPC3 and GPC5. Robust branch
partitioning suggested the likelihood that a single gene
ancestor of both subfamilies originated prior to the diver-
gence of the Eumetazoan genome (Figure S2). Notably,
in the chordate genome of the lancelet (Branchiostoma
floridae, Bflo) the single GPC-I ortholog and the single
GPC-II ortholog were identified side-by-side on a single
scaffold (BRAFLscaffold_196; GenBank: NW_003101409,
data not shown) in an arrangement reflecting both the
GPC3-GPC4 and the GPC5-GPC6 genomic clustering.
GPC3 and GPC5 are inferred to be descended from a single
chordateGPC-I ortholog andGPC4 andGPC6 from a single
GPC-II ortholog. Therefore, both loci probably arose from a
single locus. To refine the relationship among vertebrate
glypicans, we performed phylogenetic analysis by using
only glypican proteins from vertebrate genomes that
had undergone two rounds of whole-genome duplication.
Although glypicans do not appear to encode well-charac-
terized functional protein domains30 and although the
amino acid homology of mammalian proteins is as low
as 25%, the three-dimensional structure is conserved
across the family.11 Among all glypicans, the greatest sim-
ilarity at the protein level is found between GPC3 and
GPC5 and between GPC4 and GPC6 (Figure 4). In addi-
Figure 4. GPC4 and GPC6 Are the Most
Closely Related of All Glypican Proteins
(A) Phylogenetic analysis of vertebrate (2R)
glypicans was inferred via the maximum-
likelihood method. GPC1, GPC2, GPC4,
and GPC6 share a common ancestor;
GPC3 andGPC5 share a common ancestor.
GPC4 and GPC6 have undergone consider-
ably less diversification than have other
glypican proteins. The tree is drawn to
scale, and branch lengths are in the same
units as those of the evolutionary distances
used to infer the phylogenetic tree.
(B) The average amino acid identity and
similarity (brackets) of vertebrate (2R) gly-
pican proteins were determined by global
pairwise alignment. Sequence accession
numbers are indicated in Figure S1.
tion, this study has demonstrated
that GPC4 and GPC6 are the most
closely related of all glypicans.
Apart fromGPC4 (this report,Keipert
syndrome) and GPC3 (SGBS), only
GPC6has a clear associationwithMen-
delian disorders. Pathogenic variants in GPC6 cause auto-
somal-recessive omodysplasia (MIM: 258315), a skeletal
dysplasia characterized by short limbs and craniofacial ab-
normalities (frontal bossing, a depressed nasal bridge with
a short nose, and a long and prominent philtrum).31 It is
notable that there isphenotypic overlapbetween the cranio-
facial abnormalities in Keipert syndrome and those in omo-
dysplasia; however, in omodysplasia, limb abnormalities are
far more severe than in Keipert syndrome. Pathogenic
variants inGPC1,GPC2, andGPC5havenot yet been shown
to cause any Mendelian disorder, although common vari-
ants in GPC5 have been implicated in acquired nephrotic
syndrome32 and in the risk of lung cancer in never-
smokers.33 Amplification and overexpression of GPC5 has
been observed in rhabdomyosarcoma.34
We have previously identified GPC4 and GPC6 as astro-
cyte-secreted proteins that induce synapse formation in
rodent neurons.16 GPC4 and GPC6 have redundant func-
tions in vitro, but Gpc4 knockout (KO) mice have defective
synapse formation in the developing hippocampus, a part
of the brain that is enriched for Gpc4.16 In day 7–10.5
embryos, Gpc4 mRNA localizes to a range of sites that
include the anterior forebrain neuroepithelium, branchial
arches, optic and otic vesicles, limb buds, and somites.12
We performed additional studies in Gpc4-deficient mice
to look for the two primary features of Keipert syndrome:
craniofacial abnormalities and digital abnormalities. All
bone measurement experiments were approved by the
Salk Institute Institutional Animal Care and Use Commit-
tee (IACUC). In addition, we tested the mice for sensori-
neural deafness, which was observed in the originally
described Keipert-syndrome-affected family but might
not be a defining feature of the syndrome. Hearing exper-
iments were approved by Stanford University IACUC.
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Glypican-4-null (male) mice with targeted KO of exon 3
(strain MMRRC_032331-UCD) were maintained as we pre-
viously described,16,35 and 16- to 20-week-old littermate
maleGpc4KOandWTmicewere used for analysis. To deter-
mine the effect of Gpc4 loss of function on skull geometry,
we took X-rays of the skull by using a CR 7 Digital Dental
X-Ray imager and performed two sets of measurements:
(1) from the cranial aspect to the tip of the snout and (2)
for intra-orbital distance, between the medial-edge of each
orbit. There was a significant decrease in the length of the
snout in Gpc4 KO mice compared to WT (WT—9.8 5
0.1 mm, n ¼ 7 versus KO—9.05 0.2 mm, n ¼ 7, mean5
SEM, p¼ 0.014), but therewas no difference in intra-orbital
separation (WT—3.6 5 0.1 mm, n ¼ 7 versus KO—3.6 5
0.1 mm, n¼ 7, mean5 SEM, p¼ 0.64) (Figure 5A). Similar
results were obtainedwhenmeasurements for snout length
were taken with an instant-readout precision digital caliper
(Figure S3), suggesting that loss of GPC4 causes craniofacial
abnormalities in the mouse.
To determine the effect of Gpc4 loss of function on the
digits, mice were placed on a treadmill, and videos of their
paws were captured as they walked. We used GaitScan soft-
ware to analyze both fore and hind paws and analyzed a
minimum of five images per paw per mouse. We marked
the position of the base of the paw and the tip of each
phalanx. The distance between the tip of the longest pha-
lanx (#3 of 5) and base was measured for hind paws.
Because the fore paws have only four phalanges, the #3
marker was positioned equidistant between phalange 2
and 4. There was a significant decrease in the length of
both the fore and hind paws in Gpc4 KO mice compared
to WT (fore paws—WT 8.3 5 0.16 mm, n ¼ 7 versus KO
7.6 5 0.14 mm, n ¼ 7, mean 5 SEM, p ¼ 0.004; hind
paws—WT 10.4 5 0.2 mm, n ¼ 7 versus KO 9.5 5
0.2 mm, n ¼ 7, mean 5 SEM, p ¼ 0.006) (Figure 5B). We
Figure 5. Gpc4 KO Mice Exhibit Nasodi-
gital Deficits
(A) Example radiographs showing typical
skull morphology of adult WT (left) and
Gpc4 KO (right) mice. Note the shortened
snout in the KO mouse. Quantification of
radiograph data demonstrated that Gpc4
KO mice have significantly shorter snouts;
snouts were measured from the tip of the
snout to the cranial aspect. However, there
is no difference in the intra-orbital distance
in Gpc4 KO mice compared to WT.
(B)Gpc4KOmice have significantly shorter
front and rear paws.
n ¼ 7 animals per group; data combine
right and left paw to give 14 measure-
ments; statistical comparisons were made
with a two-tailed t test; error bars represent
mean5 SEM.
also measured the distance between
the phalanges, but there was no differ-
ence in the total spread of digits for
the forelimb and hindlimbs, as
measured from digit 1 to digit 5 (Figure S4). Thus, Gpc4
KO mice recapitulate the skeletal features seen in Keipert
syndrome, albeit more subtly.
To test hearing function in the Gpc4 KO mice, we per-
formed auditory brainstem response (ABR) recordings.
Mice were anesthetized, and acoustic stimuli were delivered
to the ear canals at 8, 16, and 32 kHz. Sound levels were
incremented infivedB steps from10–20dBbelow threshold
to 80 dB (for 8 and 16 kHz) or 100 dB (for 32 kHz). The
threshold for ABR was defined as the lowest stimulus level
at which repetitive waves I and V could be identified in the
response waveform. The ABR thresholds of P18 Gpc4 KO
mice were compared to those of littermate WT control
mice. There was no difference in hearing thresholds at
the 8, 16, and 32 kHz frequencies measured between the
two genotypes (Figure S5). We analyzed the ABR data at
16 kHz, within the most sensitive frequency range for
mice for peak 1 amplitudes and latencies. However, we did
not observe a shift in first peak amplitude or latency in
Gpc4 KO mice compared to controls. In addition, to test
the function of outer hair cells, we measured distortion-
product otoacoustic emissions (DPOAEs) as previously
described.36 No difference in the function of the cochlear
amplifier was revealed by DPOAE measurements between
the KO and control mice.
In conclusion,wehavedemonstrated that pathogenicvar-
iants in GPC4 underlie Keipert syndrome. The primary and
invariant features of the disorder include craniofacial and
digital abnormalities. However, despite being described in
KS1, the prototypical family, sensorineural deafness does
not appear to be consistently associated with loss of GPC4
function. We report that Gpc4 KOmice display morpholog-
ical abnormalities reminiscent of Keipert syndrome: they
have significantly shorter paw and snout lengths than WT
mice. In contrast to the relatively subtle physical phenotype
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in Gpc4-deficient mice, the zebrafish GPC4 mutant knypek
does not survive beyond 5–7 days post-fertilization; this is
due to severely reduced convergence and extension move-
ments.37 However, when these gastrulation defects are sup-
pressed by gpc4 mRNA injection, knypek embryos display
more subtle abnormalitiesof the craniofacial cartilages; these
abnormalities include shortening of the skull and jaw.38
These features are consistent with those observed in individ-
uals with Keipert syndrome and in the Gpc4 KOmice. GPC4
is the third human glypican to be linked to a genetic syn-
drome, and our data strengthen the evidence linking the
family of glypican genes to disorders of cartilage and bone
morphogenesis, information thatmaybe relevant to pheno-
types associated with dysregulation of glypicans 1, 2, and 5.
Accession Numbers
The ClinVar accession numbers for the GPC4 variants reported
in this paper are ClinVar: RCV000659264.1, RCV000659265.1,
RCV000659266.1, and RCV000659267.1.
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